| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 May 2025 | 7 Apr 2025 |
| Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2025 inter alia to consider and approve 1. the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March 2025. 2. Recommend final dividend for the year ended 31st March 2025 if any. In terms of the Companys Code of Conduct for Prevention of Insider Trading the Trading Window for dealing in the securities of the Company is closed from Tuesday 1st April 2025 till Thursday 15th May 2025 (both days inclusive) for the purpose of financial results. Please find enclosed the result dated 13th May 2025 The Board of Directors of the Company also recommended a final dividend of INR 13/- per equity share for the financial year ended 31 st March, 2025 and a special dividend of INR 3/- per equity share on the occasion of completing 90 years of the Company, taking the total dividend to INR 16/- per equity share (face value INR 2 each). The dividend, upon approval by the shareholders, will be paid to shareholders within 30 days from the date of the Annual General Meeting. The record date for the purpose of payment of final dividend, if declared, shall be 27 th June, 2025. Please find enclosed intimation Please find enclosed intimation on ESOP ESAR grant and AGM date (As Per BSE Announcement Dated on: 13.05.2025) | ||
| Board Meeting | 28 Jan 2025 | 6 Jan 2025 |
| CIPLA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 31st December 2024. Unaudited Financial Results (standalone and consolidated) for the quarter and nine months ended 31st December, 2024. Outcome of Board Meeting dated 28th January, 2025 (As Per BSE Announcement dated on 28.01.2025) | ||
| Board Meeting | 29 Oct 2024 | 1 Oct 2024 |
| CIPLA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2024 inter alia to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2024. Unaudited financial results (standalone and consolidated) for the quarter and half year ended 30th September 2024 Outcome of Board meeting dated 29th October 2024 (As Per BSE Announcement Dated on: 29/10/2024) | ||
| Board Meeting | 3 Sep 2024 | 3 Sep 2024 |
| Outcome of Board meeting held on 3rd September 2024 Change in Directors of the Company Corrigendum - Outcome of Board meeting held on 3rd September 2024 (As Per BSE Announcement Dated on 04.09.2024) | ||
| Board Meeting | 26 Jul 2024 | 4 Jul 2024 |
| CIPLA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2024 inter alia to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30th June 2024. Outcome of the Board Meeting held on 26th July 2024 (As per BSE Announcement Dated on 26/07/2024) | ||
The EBITDA margin saw a considerable improvement, moving up 184 basis points to 22.84%, from 21% in Q4 FY23.
For the quarter, net profit soared 49% on-year to ₹1,570 crore, on the back of higher revenue and better operating efficiency.
According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market
The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.
For the first nine months of FY25, Cipla's EBITDA margin stood at 26.9%, already above its full-year guidance of 24.5% to 25.5%.
Cipla reported a net profit of ₹1,303 crore, marking a 15% increase compared to the same period last year.
The VAI designation now clears the way for significant specialised launches, such as the Abraxane generic.
The company is now able to pursue important speciality medicine launches because to its VAI classification.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Tata Power, Biocon, etc.
Cipla's total research and development expenditure for the quarter reached ₹385 Crore, representing 5.5% of total sales and reflecting a 2% increase year-on-year.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
